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Objective: We conducted a meta-analysis of case-controlled prospective or retrospective studies to assess
the effect of MTHFR polymorphisms on the risk of developing endometrial cancer.
Materials and methods: PubMed, Cochrane, EMBASE, and ISI Web of Knowledge were searched (up to
March 2014) for prospective or retrospective case-controlled studies that investigated the association of
three MTHFR polymorphisms (rs180113 [C677T], rs1801131 [A1289C], and rs2274976 [G1793A]) with
endometrial cancer.
Results: The patient population included subjects from three separate countries: China, Spain, and the
USA. Only one study reported quantitative ﬁndings for MTHFR G1793A and, consequently, this poly-
morphism was not evaluated in our analysis. There were no signiﬁcant associations of any MTHFR C677T
or MTHFR A1298C alleles or genotypes with endometrial cancer (all p > 0.300).
Conclusion: This meta-analysis does not support the association of endometrial cancer with two com-
mon MTHFR polymorphisms from this patient population.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Methylenetetrahydrofolate reductase (MTHFR) is an important
enzyme controlling themetabolism of methionine and folatewhich
are essential components for nucleotide synthesis and DNA
methylation, respectively [1]. Several single nucleotide poly-
morphisms (SNPs) in the MTHFR gene have been identiﬁed. The
MTHFR C677CT (rs180113) polymorphism results in an alanine-to-
valine substitution at amino acid 222 and is associated with
reduced enzyme activity and increased thermolability [2]. This
polymorphism is thought to play an important role in the etiology
of cancer [3,4] and has been associated with increased risk for the
development of cardiovascular disease, Alzheimer's disease, adult
depression, neural tube defects in the fetus, thyroid cancer, ovarian
cancer in Asians, colorectal cancer, and hematological malignancy
[1,5e8]. The polymorphism MTHFR A1289C (rs1801131) is ay Medicine, Hangzhou First
hou, 310006, China.
).
bstetrics & Gynecology. Publishedmissense mutation that causes a glutamate-to-alanine change at
amino acid 429 in the C-terminal region of the protein that may
affect enzyme activity [9] and has been associated with leukemia,
lymphoma, and multiple myeloma risk [5,8,10]. A third poly-
morphism, MTHFR G1793A (rs2274976), results in an arginine to
glutamic acid change at amino acid 594. The functional signiﬁcance
of this change is unknown [11]. There are conﬂicting results if the
different polymorphisms are protective of or increase the risk of
certain cancers [1,7e9,12e14].
Endometrial cancer is a common invasive gynecologic cancer
and, among gynecologic malignancies, is the second-leading cause
of death worldwide [15]. A number of factors have been associated
with increased risk of endometrial cancers, including hormonal
factors, inﬂammation, familial predisposition, genetic alterations,
growth factors, diet, altered immune system, environmental fac-
tors, and oxidative stress [16e18]. Few studies have evaluated the
association of genetic polymorphisms in MTHFR and endometrial
cancer, with the ﬁndings being inconsistent [10,11,19e22]. We
conducted a meta-analysis of case-controlled prospective or
retrospective studies to assess the effect of MTHFR polymorphisms
on the risk of developing endometrial cancer.by Elsevier Taiwan LLC. All rights reserved.
Figure 1. Flow diagram of study selection. MTHFR ¼ methylenetetrahydrofolate
reductase.
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PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Cochrane
(http://www.cochrane.org), EMBASE (http://www.elsevier.com/
solutions/embase), and ISI Web of Knowledge (www.
webofknowledge.com) were searched (up to March 2014) using
a combination of the following terms: MTHFR, methylenete-
trahydrofolate reductase, endometrial carcinoma, endometrial
cancer, genetic polymorphisms. Case-control, prospective, or
retrospective studies that investigated MTHFR polymorphisms in
patients with endometrial cancer were included in the analysis.
All studies had to be published in English and must have re-
ported the quantitative primary outcome for MTHFR poly-
morphism and endometrial cancer as an odds ratio (OR). Letters,
comments, editorials, case reports, proceedings, or personal
communications were not included in the analysis. The quality of
the included studies was evaluated using the Newcastle-Ottawa
Scale (NOS) [23,24].
Data extraction
Data extracted from the included studies were: name of the ﬁrst
author, year of publication, geographic region in which the studyTable 1
Summary of basic characteristics of the included studies.
First
author (y)
Type of study Region Number of patients, Age (y)
EC/Control EC/Control EC
Liu, J.J.
(2013)
Nested
case-control
USA 572/572 30-55/30-55 Nurses aged
diagnosed w
invasive typ
Xu, W.H.
(2007)
Population-
based
case-control
China 1041/1030 30-69/30-69 Female perm
residents of
Shanghai, C
diagnosed
Paynter, R.A.
(2004)
Nested
case-control
USA 222/666 NR NR
Esteller, M.
(1997)
Hospital-
based
case-control
Spain 80/60 45e82/44e76 Female aged
selected at
Hospital of
Spain, with
diagnosis of
radiation or
therapy prio
EC ¼ endometrial cancer; MTHFR ¼ methylenetetrahydrofolate reductase; NR ¼ not repwas performed, study design, number of patients in the treatment
and control arms, patient demographics, associatedMTHFR genetic
polymorphism, whether the polymorphisms were in Hardy-
Weinberg equilibrium, and the reported OR and 95% conﬁdence
intervals (CI) for the associations of MTHFR with endometrial can-
cer. The list of potential studies were reviewed and the data
extraction performed by two independent reviewers, and a third
reviewer resolved any disagreement between the two reviewers.
Statistical analysis
Heterogeneity among the studies was assessed by the Cochran Q
and the I2 statistics. The heterogeneity was considered signiﬁcant if
either the Q statistic had p < 0.1 or I2 > 50%. When heterogeneity
was considered signiﬁcant, the random-effects model (DerSimo-
nian-Laird approach) was performed. Otherwise, the ﬁxed-effects
model (Mantel-Haenszel approach) was used. The pooled esti-
mates for OR of endometrial cancer in MTHFR 677C-to-T allele and
genotypes CT vs. CC, TT vs. CC, and CTþTT vs. CC, and for the 1298A-
to-C allele and genotypes CA vs. AA, CC vs. AA, and CAþCC vs. AA
were performed using Comprehensive Meta-Analysis version 2.0
(Biostat, Englewood, NJ, USA). A two-sided p < 0.05 was considered
statistically signiﬁcant. Publication bias was not evaluated in this
study, as ﬁve or fewer studies are insufﬁcient to detect funnel-plot
asymmetry [25]. Sensitivity analysis was performed based on the
leave-one-out approach.
Results
The database search identiﬁed 28 potential studies (Figure 1).
Twenty-three were considered irrelevant and were excluded. Five
were further evaluated and one was excluded because it did not
report ﬁndings regarding MTHFR polymorphisms. Four studies
were included in the meta-analysis [11,19e21].
All four studies were case-controlled in design and were pub-
lished between 1997 and 2013. The studies were performed in
three separate countries: USA [20,21], China [11], and Spain
(Table 1) [19]. Together the studies included 1915 endometrial
cancer cases (range, 80 to 1041) and 2328 (range, 60 to 1030)
control cases. Two studies reported that the frequency of theStudy population Hardy-Weinberg equilibrium test
Control MTHFR
677
MTHFR
1298
MTHFR
1793
30e55,
ith
e-1 EC
Nurses randomly selected
from non-EC pool and
matched menopause
status as EC subjects
NR NR NR
anent
urban
hina, EC
Female permanent resident
of urban Shanghai, China,
randomly selected from
resident registry; did not
have EC or hysterectomy
None of the genotype frequencies
for the polymorphisms deviated
signiﬁcantly from Hardy-Weinberg
equilibrium among cases or controls
NR Both MTHFR polymorphisms
were in Hardy-Weinberg
equilibrium in the cases
and the controls
NR
45e82,
Valld'Hebron
Barcelona,
proven
EC and no
hormonal
r to surgery
Female selected at
Valld'Hebron Hospital of
Barcelona, Spain, with no
clinical or histological
malignancy and no history
of any other cancer
NR NR NR
orted.
Table 2
Summary for the reported associations between MTHFR and EC from the included studies.
1st author
(year of publication)
MTHFR 677 e CC/ CT/ TT
or OR (95% CI)
MTHFR 1298 e AA/ AC/ CC
or OR (95% CI)
MTHFR 1793 e GG/ GA/ AA
or OR (95% CI)
EC Control EC Control EC Control
Liu, J.J. (2013) OR (T to C): 1.06 (0.89, 1.27) OR (C to A): 1.03 (0.87, 1.23) NR NR
Xu, W.H. (2007) 356/506/167 337/521/158 699/300/37 705/280/34 856/174 855/158
OR (CT to CC): 0.9 (0.8e1.1)b
OR (TT to CC): 1.0 (0.8e1.3)b
OR (AC to AA): 1.1 (0.9e1.3)b
OR (CC to AA): 1.1 (0.7e1.8)b
OR (AGþAA to GG): 1.1 (0.9e1.4)
Paynter, R.A. (2004) 97/99/22 299/296/68 102/88/29 302/285/78 NR NR
OR (CT to CC): 1.10 (0.75e1.60)a
OR (TT to CC): 1.11 (0.62e1.99)a
OR (AC to AA): 0.85 (0.59e1.22)a
OR (CC to AA): 0.88 (0.51e1.52)a
Esteller, M. (1997) 25/43/12 34/20/6 NR NR NR NR
OR (CTþTT to CC): 2.8 (1.36, 6.14)
CI ¼ conﬁdence interval; EC ¼ endometrial cancer; MTHFR ¼ methylenetetrahydrofolate reductase; NR ¼ not reported; OR ¼ odds ratio.
a Additionally adjusted for body mass index prior to diagnosis, weight gain since age 18, age at menarche, ages at ﬁrst birth and last birth, age at menopause, parity,
pack-years of smoking, and ﬁrst-degree family history of endometrial cancer or colon cancer.
b Adjusted for age.
Figure 2. Meta-analyses for the odds ratios of MTHFR 677 (A) C-to-T allele, (B) geno-
type CT vs. CC, (C) genotype TT vs. CC, and (D) genotype CTþTT vs. CC. The random-
effects model was performed if either the Q statistic with p < 0.1 or I2 > 50%. Other-
wise, the ﬁxed-effect model was performed. CI ¼ conﬁdence interval.
Figure 3. Meta-analysis for the odds ratio of MTHFR 1298 (A) A-to-C allele, (B) ge-
notype AC vs. AA, (C) genotype CC vs. AA, and (D) genotype ACþCC vs. AA. The
random-effects model was performed if either the Q statistic with p < 0.1 or I2 > 50%.
Otherwise, the ﬁxed-effect model was performed. CI ¼ conﬁdence interval.
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Table 3
The corresponding sensitivity-analyses for the meta-analyses of MTHFR 677 and
1298.
Study name,
ﬁrst author (y)
The pooled estimates
and related statistics
with one study removed
OR (95% CI) Z p
MTHFR 677
Allele C to T
Liu, J.J. (2013) 1.12 (0.86e1.46) 0.863 0.388
Xu, W.H. (2007) 1.16 (0.89e1.52) 1.124 0.261
Paynter, R.A. (2004) 1.12 (0.89e1.41) 0.989 0.322
Esteller, M. (1997) 1.01 (0.92e1.11) 0.193 0.847
Overall pooled
estimate (random)
1.07 (0.91e1.26) 0.859 0.390
MTHFR 677
genotype
CT vs. CC
Xu, W.H. (2007) 1.70 (0.66e4.39) 1.091 0.275
Paynter, R.A. (2004) 1.55 (0.50e4.77) 0.759 0.448
Esteller, M. (1997) 0.95 (0.80e1.13) 0.551 0.581
Overall pooled
estimate (random)
1.26 (0.78e2.03) 0.949 0.342
MTHFR 677
genotype
TT vs. CC
Xu, W.H. (2007) 1.35 (0.81e2.26) 1.137 0.256
Paynter, R.A. (2004) 1.05 (0.82e1.36) 0.408 0.683
Esteller, M. (1997) 1.02 (0.80e1.29) 0.144 0.886
Overall pooled
estimate (ﬁxed)
1.06 (0.84e1.34) 0.514 0.607
MTHFR 677
genotype
CTþTT vs. CC
Xu, W.H. (2007) 1.63 (0.59e4.49) 0.948 0.343
Paynter, R.A. (2004) 1.56 (0.52e4.65) 0.799 0.424
Esteller, M. (1997) 0.96 (0.82e1.13) 0.496 0.620
Overall pooled
estimate (random)
1.22 (0.80e1.86) 0.916 0.360
MTHFR 1298
Allele A to C
Liu, J.J. (2013) 1.05 (0.92e1.20) 0.715 0.475
Xu, W.H. (2007) 1.02 (0.89e1.17) 0.318 0.750
Paynter, R.A. (2004) 1.05 (0.93e1.18) 0.823 0.410
Overall-pooled
estimate (ﬁxed)
1.04 (0.94e1.16) 0.771 0.441
CI ¼ conﬁdence interval; OR ¼ odds ratio.
Table 4
Quality assessment of included studies.
Liu, J.J. Xu, W.H. Esteller, M. Paynter, R.A.
Selection *** *** ** ****
Comparability * * * **
Exposure *** *** *** ***
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G1793A were in Hardy-Weinberg equilibrium [11,20].
The OR for the association of MTHFR polymorphisms and
endometrial cancer was reported in four studies for MTHFR C677T
and in three studies forMTHFR A1298C (Table 2). Only the study of
Xu et al [11] reported the association of MTHFR G1793A with
endometrial cancer. Therefore, the meta-analysis did not include
this polymorphism in the analysis (Figures 2 and 3).
The pooled data for both MTHFR C677T and MTHFR A1298C
showed heterogeneity (p < 0.01 and I2 > 50%), hence a random-
effects model was used for the analyses. There was no signiﬁcant
association of any of the alleles or genotypes of MTHFR C677T or
MTHFR A1298C with endometrial cancer [all p > 0.300, (Figures 2
and 3)]. Sensitivity analysis using the leave-one-out approach
found that no single study overly inﬂuenced the ﬁndings and that
the results were reliable (Table 3).
Using the NOS for case-control studies, the quality of the design
of each study, regarding selection of the study groups, compara-
bility of the groups, and ascertainment of exposure, was assessed
(Table 4) [23]. The study of Panter et al [20] was of high quality,
having the maximum score for all three criteria (4 stars for selec-
tion, 2 for comparability, and 3 for exposure), and that of Esteller
et al [19] was of lower quality relative to the other studies, with two
stars for selection and one star for comparability.
Discussion
Although endometrial cancer is a common female malignancy,
little is known regarding genetic susceptibility factors. We per-
formed a meta-analysis to evaluate the association of endometrial
cancer with two common polymorphisms in the MTHFR gene:
MTHFR C677T and MTHFR A1298C. Four case-controlled studies
were included in the meta-analysis, encompassing 1915 endo-
metrial cancer cases and 2328 controls. Our meta-analysis found
no signiﬁcant association of any of the alleles or genotypes of
MTHFR C677T and MTHFR A1298C with endometrial cancer (all
p > 0.300).
The four studies included in this meta-analysis differed in their
ﬁndingswith regard to the relationship ofMTHFRC677TandMTHFR
A1298C with endometrial cancer. Liu et al [21] performed a pro-
spective cohort analysis that investigated whether SNPs that are
involved in one-carbon metabolism inﬂuence the association of
dietary factors with endometrial cancer in women from the USA.
They genotyped 572 endometrial cancer cases and matched con-
trols and examined 29 mostly nonsynonymous SNPs in genes
involved in one-carbon metabolism. For MTHFR, they evaluated
MTHFR C677T and MTHFR A1298C. They found that MTHFR C677T
and MTHFR A1298C SNPs were signiﬁcantly associated with endo-
metrial cancer (p  0.05), however, there was a suggestion that the
677-TT or 1298-CC genotypes had a protective effect for folate,
vitamin B2, vitamin B6, vitamin B12, and alcohol intake and
endometrial cancer.
Xu et al [11] also did not ﬁnd a relationship between MTHFR
SNPs and endometrial cancer. Their study was a population-based
case-controlled study that investigated the individual and joint
effects of MTHFR C677T, MTHFR A1298AC, and MTHFR G1793A
polymorphisms with dietary folate and other methyl-related nu-
trients on endometrial cancer risk. They genotyped 1041 newly
diagnosed endometrial cancer cases and 1030 controls from
women aged 39 to 69 years from Shanghai, China. They found no
association between the risk of endometrial cancer and the derived
haplotypes of the MTHFR SNPs. However, they did ﬁnd that folate
intake may modify the effect of MTHFR polymorphisms on endo-
metrial cancer risk, as women carrying the MTHFR A1298C or
MTHFR G1793A allele and having high folate intake had the lowestrisk of endometrial cancer (p-interaction¼ 0.08 and p-interaction¼ 0.03,
respectively).
Similarly, Paynter et al [20] investigated 201 endometrial cancer
cases and 603 controls from the USA and found little or no asso-
ciation between the MTHFR genotype and endometrial cancer. For
MTHFR C677T, the adjusted OR (95% CI) for comparing the presence
of the T allele to the CC homozygotes was 1.10 (0.77e1.57) and for
MTHFR A1298C, the adjusted OR (95% CI) for the presence of the C
allele compared to the AA homozygotes was 0.85 (0.61e1.20).
In contrast, the study of Esteller et al [22] did ﬁnd an association
of MTHFR C677T with endometrial cancer in a Spanish population.
The study of Esteller et al [19] included 80 patients with endome-
trial cancer and 60 controls. They found that a signiﬁcant increase
in endometrial cancer in patients carrying the 677-C/T or 677-T/T
genotypes {alanine-to-valine substitution, [OR (95% CI); 2.88 (1.36-
6.14)]; p ¼ 0.002}. They also found a signiﬁcant association of the
677-T allele and undifferentiated cellular grade endometrial cancer
(p ¼ 0.03).
The difference between the studies may reﬂect the different
populations investigated, as geographical regions may have
different genetic and environmental factors that might affect the
ﬁndings [10]. For example, Pu et al [7] found that theMTHFR C667T
polymorphismwas associated with ovarian cancer in Asian, but not
in Caucasian women [7]. Additionally, the etiology of endometrial
cancer is not well understood and multiple risk factors can
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dietary intake, may also be geographically dependent, which could
also inﬂuence ﬁndings. Xu et al [11] found that women with the
lowest risk of endometrial cancer carried the MTHFR A1298C allele
and had the highest intake of both folate and riboﬂavin. The type of
cancer may also inﬂuence ﬁndings, as Esteller et al [19] found the
greatest association of MTHFR C677T with endometrial cancer in
women with poorly or moderately differentiated tumors as
compared with those having well-differentiated tumors [19]. The
three studies that found no association of the two MTHFR poly-
morphisms with endometrial cancer were also of higher quality in
design than the study of Paynter et al [20].
There are several limitations to this study that should be
considered when interpreting the results. Only four studies were
included in themeta-analysis. Therewas insufﬁcient information in
the four studies to perform subgroup analysis to investigate the
effect of folate consumption and ethnicity on outcomes. This meta-
analysis only investigated the effect of two polymorphisms (C677T
and A1298C) and did not evaluate the effect of other poly-
morphisms or the joint effect of the two included polymorphisms
on risk of developing endometrial cancer. Our ﬁndings point to the
need for additional controlled studies to examine the relationship
of MTHFR polymorphisms and endometrial cancer.
In conclusion, this meta-analysis is consistent with MTHFR
C677T and MTHFR A1298C polymorphisms not being signiﬁcantly
associated with an increased risk of endometrial cancer. Larger
well-designed studies are needed to investigate the association of
these MTHFR polymorphisms with susceptibility for endometrial
cancer.
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